Role of the tPA/plasmin System in Alzheimers Disease
tPA/纤溶酶系统在阿尔茨海默病中的作用
基本信息
- 批准号:7480226
- 负责人:
- 金额:$ 37.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-25 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:Abeta clearanceAllelesAlteplaseAlzheimer&aposs DiseaseAmyloidAmyloid beta-ProteinAmyloid beta-Protein PrecursorAncrodAnimalsAttenuatedBehavioralBlood VesselsBrainCardiovascular systemDementiaDepositionDepressed moodDevelopmentDiseaseDisease ProgressionEndopeptidasesEpidemiologic StudiesEpidemiologyExcisionFamily suidaeFibrinFibrinogenFigs - dietaryFunctional disorderGenesGeneticGenotypeGoalsHumanImpaired cognitionIndividualInflammationInterventionKnock-outKnockout MiceLeadLongevityMetforminModelingMouse StrainsMusNerve DegenerationPathogenesisPathologyPathway interactionsPeptide HydrolasesPeptidesPlasminPlasminogenPlasminogen ActivatorPlasminogen Activator Inhibitor 1Plasminogen InactivatorsPlayProductionProtein OverexpressionProtein PrecursorsProteinsPsyche structurePurposeResearch PersonnelRisk FactorsRoleSerine Proteinase InhibitorsSerpinsSnake VenomsStaining methodStainsSuggestionSus scrofaSystemTestingTg2576Therapeutic AgentsTherapeutic InterventionThinkingToxic effectTransgenesTransgenic MiceTransgenic OrganismsUp-RegulationWeekWild Type MouseWorkagedcerebrovascularconceptin vivoinhibitor/antagonistmouse modelneurotoxicpupresearch study
项目摘要
DESCRIPTION (provided by applicant): The overall hypothesis of this proposal is that the tissue plasminogen activator/plasminogen (tPA/plg) fibrinolytic cascade, a proteolytic system which has been implicated in the clearance of amyloid-beta (A-beta) peptide, is an important pathway to investigate for developing possible therapeutic agents against Alzheimer's disease (AD). The abnormal deposition of A-beta in the parenchyma and blood vessels of the brain is a pathological hallmark of AD, the most common cause of dementia and cognitive decline in the aged. Additionally, epidemiological studies indicate that diseases that compromise the circulatory system are risk factors for the development of AD, and imply that AD has a cerebrovascular component. The objectives of this proposal are to investigate the role of the tPA/plg system in the progression of AD-like pathology in transgenic mice overexpressing the amyloid-beta precursor protein (A-betaPP). The tPA/plg system activity is depressed in AD transgenic mice and in individuals with AD, due to the expression of plasminogen activator inhibitor-1 (PAl-l), a protein overexpressed during inflammation, commonly seen in AD. To accomplish this goal, we propose three specific aims. First, we plan to investigate the effects of the loss of tPA, plg, or PAl-1 expression in A-betaPP transgenic mice in a C57/BI6 background. Second, we plan to investigate the role of fibrin deposition in exacerbating the pathology and cerebrovascular dysfunction in AD. Third, we plan to identify new compounds that block the interaction of PAl-1 and tPA, and to test these, along with known PAl-1 inhibitors, for their effects in AD mouse models. These experiments will take advantage of transgenic and knockout mouse lines as in vivo paradigms for the development of possible therapeutic intervention strategies, targeting the tPA/plasmin cascade, against AD progression
描述(由申请人提供):该建议的总体假设是组织纤溶酶原激活剂/纤溶酶原(TPA/PLG)纤维蛋白溶解级联反应,这是一种蛋白水解系统,该系统与清除淀粉样β(A-Beta)肽的清除有关,是针对Alapeation的重要途径。 A-beta在实质中的异常沉积和大脑的血管是AD的病理标志,这是老年痴呆症和认知能力下降的最常见原因。此外,流行病学研究表明,损害循环系统的疾病是AD发展的危险因素,这意味着AD具有脑血管成分。该提案的目标是研究TPA/PLG系统在过表达淀粉样蛋白β前体蛋白(A-BetApp)的转基因小鼠中AD样病理学进展中的作用。由于纤溶酶原激活剂抑制剂-1(PAL-L)的表达,TPA/PLG系统的活性在AD转基因小鼠和AD个体中抑郁,这种蛋白质在炎症过程中过表达,通常在AD中看到。为了实现这一目标,我们提出了三个具体目标。首先,我们计划研究C57/BI6背景中A-BetApp转基因小鼠TPA,PLG或PAL-1表达丢失的影响。其次,我们计划研究纤维蛋白沉积在加剧AD中病理学和脑血管功能障碍中的作用。第三,我们计划鉴定阻断PAL-1和TPA相互作用的新化合物,并与已知的PAL-1抑制剂一起测试它们在AD小鼠模型中的影响。这些实验将利用转基因和基因敲除小鼠系作为体内范式,以开发可能的治疗干预策略,靶向TPA/plasmin级联反应AD的进展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SIDNEY STRICKLAND其他文献
SIDNEY STRICKLAND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SIDNEY STRICKLAND', 18)}}的其他基金
Role of the tPA/plasmin System in Alzheimers Disease
tPA/纤溶酶系统在阿尔茨海默病中的作用
- 批准号:
7112914 - 财政年份:2004
- 资助金额:
$ 37.06万 - 项目类别:
相似国自然基金
等位基因聚合网络模型的构建及其在叶片茸毛发育中的应用
- 批准号:32370714
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于等位基因非平衡表达的鹅掌楸属生长量杂种优势机理研究
- 批准号:32371910
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
- 批准号:82300353
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACR11A不同等位基因调控番茄低温胁迫的机理解析
- 批准号:32302535
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠杆菌多粘菌素异质性耐药中phoPQ等位基因差异介导不同亚群共存的机制研究
- 批准号:82302575
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A Novel Intervention Strategy for Stroke with RTL Therapy
采用 RTL 疗法治疗中风的新型干预策略
- 批准号:
8515537 - 财政年份:2009
- 资助金额:
$ 37.06万 - 项目类别:
A Novel Intervention Strategy for Stroke with RTL Therapy
劳逸结合治疗中风的新型干预策略
- 批准号:
8392585 - 财政年份:2009
- 资助金额:
$ 37.06万 - 项目类别:
Clotting genetic variant, hormones and venous thrombosis
凝血遗传变异、激素和静脉血栓形成
- 批准号:
7217278 - 财政年份:2004
- 资助金额:
$ 37.06万 - 项目类别:
Role of the tPA/plasmin System in Alzheimers Disease
tPA/纤溶酶系统在阿尔茨海默病中的作用
- 批准号:
7277643 - 财政年份:2004
- 资助金额:
$ 37.06万 - 项目类别:
Genetic analysis of heparan sulfate in vascular biology
硫酸乙酰肝素在血管生物学中的遗传分析
- 批准号:
7510385 - 财政年份:
- 资助金额:
$ 37.06万 - 项目类别: